These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20642980)

  • 1. Chronic myeloproliferative neoplasm with concurrent BCR-ABL translocation and JAK2 mutation.
    Siddiqui NS; Ssiddiqui HS; Qurat-Ul-Ain ; Siddiqui SA
    J Coll Physicians Surg Pak; 2010 Jun; 20(6):423. PubMed ID: 20642980
    [No Abstract]   [Full Text] [Related]  

  • 2. Two alternatively spliced 5'BCR/3'JAK2 fusion transcripts in a myeloproliferative neoplasm with a three-way t(9;18;22)(p23;p11.3;q11.2) translocation.
    Impera L; Lonoce A; Fanfulla DA; Moreilhon C; Legros L; Raynaud S; Storlazzi CT
    Cancer Genet; 2011 Sep; 204(9):512-5. PubMed ID: 22018274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
    Go RS
    Leukemia; 2007 Sep; 21(9):2051; author reply 2052. PubMed ID: 17597806
    [No Abstract]   [Full Text] [Related]  

  • 4. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
    Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
    Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
    [No Abstract]   [Full Text] [Related]  

  • 5. BCR/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond.
    Chang CC
    Arch Pathol Lab Med; 2006 Aug; 130(8):1123-5. PubMed ID: 16879012
    [No Abstract]   [Full Text] [Related]  

  • 6. JAK2-V617F and BCR-ABL--double jeopardy?
    Krämer A
    Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
    [No Abstract]   [Full Text] [Related]  

  • 7. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
    He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
    Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.
    Duployez N; Nibourel O; Ducourneau B; Grardel N; Boyer T; Bories C; Darre S; Coiteux V; Berthon C; Preudhomme C; Roche-Lestienne C
    Eur J Haematol; 2016 Oct; 97(4):399-402. PubMed ID: 26935241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
    Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
    Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
    Ammatuna E; Ottone T; Zaza S; Lavorgna S; Grillo R; Curzi P; Panetta P; Federici G; Amadori S; Lo-Coco F
    Ann Hematol; 2007 May; 86(5):355-61. PubMed ID: 17285276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia.
    Cirmena G; Aliano S; Fugazza G; Bruzzone R; Garuti A; Bocciardi R; Bacigalupo A; Ravazzolo R; Ballestrero A; Sessarego M
    Cancer Genet Cytogenet; 2008 Jun; 183(2):105-8. PubMed ID: 18503828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders.
    Bang SM; Ahn JY; Park J; Yoo SJ; Park SH; Nam EM; Park PW; Seo YH; Cho EK; Shin DB; Lee JH
    Korean J Intern Med; 2006 Dec; 21(4):219-24. PubMed ID: 17249502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.
    Kim YK; Shin MG; Kim HR; Yang DH; Cho SH; Lee JJ; Chung IJ; Ryang DW; Kim HJ
    Leuk Res; 2008 Jun; 32(6):993-5. PubMed ID: 18055011
    [No Abstract]   [Full Text] [Related]  

  • 14. Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ; Kim DY; Lee JH; Lee KH
    Ann Lab Med; 2013 May; 33(3):229-32. PubMed ID: 23667855
    [No Abstract]   [Full Text] [Related]  

  • 15. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
    Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K
    Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
    Borovecki A; Skrtić A; Paro MM; Lasan R; Dominis M
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage.
    Suárez EU; Piris MÁ; Rodríguez-Pinilla SM; García JF; López-Lorenzo JL; Cornago-Navascués J; Salgado-Sánchez R; Castaño-Bonilla T; Mata-Serna R; Alonso-Domínguez JM; Llamas P
    Ann Hematol; 2024 May; 103(5):1797-1799. PubMed ID: 38308706
    [No Abstract]   [Full Text] [Related]  

  • 19. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
    James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
    Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [JAK2 mutation in myeloproliferative disorders].
    Inokuchi K
    Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.